In vitro evaluation of the antitumor activity of axitinib in canine mammary gland tumor cell lines

Axitinib, a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase 1,2 and 3, is used in chemotherapy because it inhibits tumor angiogenesis by blocking the VEGF/VEGFR pathway. In veterinary medicine, attempts have been made to apply tyrosine kin...

Full description

Saved in:
Bibliographic Details
Published in:Journal of veterinary science (Suwŏn-si, Korea) 2024, 25(1), , pp.0-0
Main Authors: Lee, Hye-Gyu, Lim, Ga-Hyun, An, Ju-Hyun, Park, Su-Min, Seo, Kyoung-Won, Youn, Hwa-Young
Format: Article
Language:English
Subjects:
Original
수의학
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Axitinib, a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase 1,2 and 3, is used in chemotherapy because it inhibits tumor angiogenesis by blocking the VEGF/VEGFR pathway. In veterinary medicine, attempts have been made to apply tyrosine kinase inhibitors with anti-angiogenic effects to tumor patients, but there are no studies on axitinib in canine mammary gland tumors (MGTs). This study aimed to confirm the antitumor activity of axitinib in canine mammary gland cell lines. We treated canine MGT cell lines (CIPp and CIPm) with axitinib and conducted CCK, wound healing, apoptosis, and cell cycle assays. Additionally, we evaluated the expression levels of angiogenesis-associated factors, including , , , and , using quantitative real-time polymerase chain reaction. Furthermore, we collected canine peripheral blood mononuclear cells (PBMCs), activated them with concanavalin A (ConA) and lipopolysaccharide (LPS), and then treated them with axitinib to investigate changes in viability. When axitinib was administered to CIPp and CIPm, cell viability significantly decreased at 24, 48, and 72 h ( < 0.001), and migration was markedly reduced (6 h, < 0.05; 12 h, < 0.005). The apoptosis rate significantly increased ( < 0.01), and the G2/M phase ratio showed a significant increase ( < 0.001). Additionally, there was no significant change in the viability of canine PBMCs treated with LPS and ConA. In this study, we confirmed the antitumor activity of axitinib against canine MGT cell lines. Accordingly, we suggest that axitinib can be applied as a new treatment for patients with canine MGTs.
ISSN:1229-845X
1976-555X
DOI:10.4142/jvs.23191